Multicenter Phase II Trial of Durvalumab (MEDI4736) With Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer (DTP Trial)

Investigator: Jenny Chang, MD

Study Coordinator: Rabia Hashmani

Status: Open Not Enrolling Number: NCT03820141

Phone: 346.238.5894

Protocol Number: Pro00020917


The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer.
More to Explore